AG Mazák on AstraZeneca

Case C‑457/10 P, AstraZeneca AB and AstraZeneca plc v European Commission, here. 

AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law?

J. Drexl, here. 

Italian Pfizer Case (3)

T. Graf, here.
(1 here and 2 here)

Economic Analysis of Pay-for-Delay Settlements and Their Legal Ruling

L. Gratz, here. 

Evolution or Revolution? The Italian Competition Authority and the Pfizer Decision: A Reply to Thomas Graf

S. Grassani, here. 

Strong medicine for law breakers – NDRC’s first antitrust action in the pharmaceutical sector under the Anti-monopoly law

Hogan Lovells, Antitrust, Competition and Economic Regulation
Client Quarterly Newsletter, p. 18 f., here. 

EU Commission closes procedural case against Servier

Here. From the press release: "In light of Servier's arguments which would require significant further investigation, the Commission has decided to close the case, and instead focus on the substantive enforcement of competition rules in a number of pending cases, including one involving Servier". Was the Commission flabbergasted  by Servier's backfire?

AGCM: sanzionata Pfizer con una multa di 10,6 milioni di euro per abuso di posizione dominante

Provvedimento qui.

NDRC Fined Two Pharmaceutical Companies for Abusive Conducts

chinalawinsight.com, here. 

WTO TRIPS Council: Ecuador questions the European Union on Italian compulsory licenses

KEI, here.

Bruselas investiga un posible pacto entre Johnson & Johnson y Novartis

europaexpress.es, aquì.

FTC Staff Says Proposed New York Legislation Would Reduce Competition and Likely Lead to Higher Prescription Drug Costs

Here.